Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive finan ...

With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...

Trinity Biotech (TRIB) announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose ...

Trinity Biotech (TRIB) has obtained an additional $4M in debt financing from its primary lender, Perceptive Advisors. The additional liquidity ...

In other recent news, Trinity Biotech reported a 3% year-on-year revenue growth in its third quarter of 2024, amounting to $15.2 million. Despite a post-tax net loss of $4.8 million, the company ...